CNS Pharma Announces 1-For-12 Reverse Split Of Its Common Stock
                                Author: Benzinga Newsdesk | July 18, 2025 07:01am
                                
				
                                                
                                
                                CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-12 reverse split of its common stock. Beginning on July 22, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP" but will trade under the following new CUSIP number: 18978H508.
                                                                                    Posted In: CNSP